Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SYT-510
Therapeutic Area : Psychiatry/Psychology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Synendos Therapeutics AG Granted EMA Authorization for SYT-510 Clinical Trial
Details : SYT-510, a first-in-class inhibitor, targets the Endocannabinoid System to restore healthy brain function. It is being studied in preclinical trials for anxiety, PTSD, and mood-related disorders.
Product Name : SYT-510
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 18, 2024
Lead Product(s) : SYT-510
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SYT-510
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : Ysios Capital
Deal Size : $26.6 million
Deal Type : Series A Financing
Synendos Therapeutics Expands Series A to CHF 24 Million with New Investment
Details : This investment brings total Series A financing to CHF 24 million to complete pre-clinical development and progress lead candidate through proof-of-concept clinical studies. Synendos is advancing the preclinical and clinical development of SYT-510.
Product Name : SYT-510
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 20, 2021
Lead Product(s) : SYT-510
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : Ysios Capital
Deal Size : $26.6 million
Deal Type : Series A Financing
Lead Product(s) : SYT-510
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Kurma Partners
Deal Size : $22.4 million
Deal Type : Series A Financing
Synendos Therapeutics Raises CHF 20 Million in Series A Financing
Details : Financing will allow Synendos Therapeutics to complete pre-clinical development and progress lead candidate through proof of concept clinical study.
Product Name : SYT-510
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 11, 2020
Lead Product(s) : SYT-510
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Kurma Partners
Deal Size : $22.4 million
Deal Type : Series A Financing